RxDoctor Payments Data

Sergey Wortman, MD

Physical Medicine & Rehabilitation · New Bedford, MANPI 1285730671

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Biodelivery Sciences International, Inc. at 49.7% of the total. Reporting peaked in 2020 at $297 and has fallen 84.9% since, to $45 in 2025.

$691in general payments, 2019–2025

Across 76 payments — averaging $9.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biodelivery Sciences International, Inc.$343
  • Collegium Pharmaceutical, Inc.$181
  • Valinor Pharma, LLC$111
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$56

What the payments were for

  • Food & beverage$691100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$691 in reported general payments places this provider in the 75th percentile of 244 physical medicine & rehabilitation providers in Massachusetts.

See all physical medicine & rehabilitation providers in Massachusetts

Medicare billing

Part B allowed, 2024
$68,077
Medicare patients
156
Services billed
647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl125$91,998
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen942$32,624
Oxycodone Hcl1,252$26,456
Xtampza ErOxycodone Myristate28$24,458
LinzessLinaclotide23$15,189
BelbucaBuprenorphine Hcl13$14,450
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen217$6,678
Lidocaine23$3,664
Morphine Sulfate ErMorphine Sulfate123$3,446
Gabapentin241$2,726
Fentanyl13$1,676
Diclofenac Sodium84$1,307
Morphine Sulfate55$1,295
Baclofen100$1,040
Methylprednisolone119$960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$181$38,90841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 244 physical medicine & rehabilitation providers in Massachusetts.

Other physical medicine & rehabilitation in New Bedford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →